Supramolecular Nanomaterials for Drug Delivery, Imaging, and Immunoengineering 1

Timeslot: Thursday, April 12, 2018 - 4:15pm to 6:15pm
Track: Drug Delivery
Room: Grand Ballroom D


Due to the versatility and diversity of their materials properties, a wide range of biomedical applications have emerged in recent years using supramolecular nanomaterials. The bottom-up approach to designing functional objects at the nanoscale has been used to develop individual nanoparticles or to produce highly oriented complexes for a growing number of applications including drug delivery, imaging, theranostics, vaccines, and cancer immunotherapy. In addition, there are exciting opportunities for local therapeutic modulation. This session highlights recent advances in nanomaterials design aimed to enhance the in vivo delivery of therapeutic or imaging payloads for a variety of diseases including those affecting the skin, gastrointestinal and respiratory tracts, cardiovascular system, cancer, and other diseased tissues.


  • 4:15 p.m. 275. Protein Mimetic and Anticancer Properties of Monocyte-targeting Peptide Amphiphile Micelles, C. Poon*(1), S. Chowdhuri(1), C. Kuo(2), Y. Fang(2), F. Alenghat(2), D. Hyatt(2), K. Kani(1), M. Gross(1), E. Chung(1); (1)University of Southern California, Los Angeles, CA, (2)University of Chicago, Chicago, IL

  • 4:30 p.m. 276. Crosslinked Peptide Nanoclusters for Efficient Delivery of Cancer Antigen, A Tsoras*, J Champion; Georgia Institute of Technology, Atlanta, GA

  • 4:45 p.m. 277. H2O2-Activatable Contrast-Enhanced Photoacoustic Imaging and Antithrombotic Therapy using Molecularly Engineered Theranostic Nanoparticles, D Lee*; Chonbuk National University, Jeonju, Republic of Korea

  • 5:00 p.m. 278. Multi-stage lymphatic delivery system augments lymphoma immunotherapy, A. Schudel*(1), C. Higginson(2), M. Yau(1), M. Finn(1), S. Thomas(1); (1)Georgia Institute of Technology, Atlanta, GA, (2)Univeristy of California Berkeley, Berkeley, CA

  • 5:15 p.m. 279. Galectin-enzyme fusion nanoassemblies for prolonged injection site biocatalysis via local glycan binding, S Farhadi, E Bracho-Sanchez, S Freeman, B Keselowsky, G Hudalla*; University of Florida, Gainesville, FL

  • 5:30 p.m. 280. Self-Assembling Nanoparticles with Enhanced Stability, H Acar*(1), G Benuska(2), L Ludwig(2), J LaBelle(2), M Tirrell(2); (1)University of Oklahoma, Norman, OK, (2)The University of Chicago, Chicago, IL

  • 5:45 p.m. 281. Amphiphilic Micelle-Mediated Silencing of MGMT in Glioblastoma Multiforme Tumor Cells In Vivo, A Alexander-Bryant(1), B Hourigan(1), M Lynn(2), J Lee*(1); (1)Clemson University, Clemson, SC, (2)Greenville Health System, Greenville, SC

  • 6:00 p.m. 282. Nanoscale Peptide Self-assemblies Boost BCG-primed Cellular Immunity against Mycobacterium tuberculosis, C Chesson(1), R Nusbaum(2), M Huante(3), J Endsley(3), J Rudra*(3); (1)MD Anderson Cancer Center, Houston, TX, (2)University of Pennsylvania, Philadelphia, PA, (3)University of Texas Medical Branch, Galveston, TX